Viking Global Investors LP recently announced the acquisition of new stake in RayzeBio Inc. (NASDAQ:RYZB). This fresh investment now brings its stake to 11.09% valued currently at $158.63 million. In addition, Wellington Management Co. LLP raised its holdings by 3.88 million to 3.88 million shares.
With over 9.18 million RayzeBio Inc. (RYZB) shares trading Tuesday and a closing price of $61.40 on the day, the dollar volume was approximately $563.64 million. Currently, there are 55.32M common shares owned by the public and among those 30.05M shares have been available to trade.
The top 3 mutual fund holders in RayzeBio Inc. are American Funds Small Cap World Fu, AB Small Cap Growth Portfolio, and Franklin Small Cap Growth Fund. American Funds Small Cap World Fu owns 1.1 million shares of the company’s stock, all valued at over $26.34 million. The company bought an additional 1.1 million shares recently to bring their total holdings to about 1.84% of the shares outstanding. AB Small Cap Growth Portfolio sold 12232.0 shares to see its total holdings shrink to 0.64 million shares valued at over $15.35 million and representing 1.07% of the shares outstanding. Franklin Small Cap Growth Fund bought 46800.0 shares to bring its total holdings to over 0.45 million shares at a value of $10.75 million. Franklin Small Cap Growth Fund now owns shares totaling to 0.75% of the shares outstanding.
Shares of RayzeBio Inc. (NASDAQ: RYZB) opened at $61.26, up $30.69 from a prior closing price of $30.57. However, the script later moved the day high at 62.09, up 100.85%. The company’s stock has a 5-day price change of 129.19% and 231.71% over the past three months. It has a 12-month low price of $17.95 and touched a high of $31.11 over the same period. RYZB has an average intraday trading volume of 285.69K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 139.73%, 170.00%, and 177.29% respectively.
Institutional ownership of RayzeBio Inc. (NASDAQ: RYZB) shares accounts for 47.32% of the company’s 55.32M shares outstanding. Mutual fund holders own 39.15%, while other institutional holders and individual stakeholders account for 8.09% and 0.62% respectively.
It has a market capitalization of $3.67B. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.00% over the week and 7.66% over the month.
Analysts forecast that RayzeBio Inc. (RYZB) will achieve an EPS of -$0.65 for the current quarter, -$1.08 for the next quarter and -$3.38 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.96 while analysts give the company a high EPS estimate of -$0.35.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate RayzeBio Inc. (RYZB) as a “Strong Buy” at a consensus score of 1.40. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 1 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”
